Autobio Diagnostics Co., Ltd.
603658
Rang in aandelen
#4904
Autobio Diagnostics Co., Ltd. specializes in the full lifecycle of clinical... Autobio Diagnostics Co., Ltd. specializes in the full lifecycle of clinical diagnostic products, from their initial research and development to manufacturing and market distribution. Their diverse offerings encompass a range of reagents for immunoassay, biochemistry, microbiology, and in-vitro diagnostics (IVD). Additionally, they provide advanced automated and semi-automated instrumentation, alongside comprehensive medical laboratory solutions. Notable immunoassay products include the AutoLumo A2000 Plus automatic chemiluminescence immunoassay analyzer, automated microplate chemiluminescent enzyme immunoassays, LUmo luminometers, PHOmo microplate readers, and iWO microplate washers. Within their microbiology division, they offer automated blood culture systems, blood culture bottles, AUTOMIC strips, and mycoplasma IES. Founded in 1998, the company originally operated as Lifeclone Diagnostics Co., Ltd. before adopting its current name, Autobio Diagnostics Co., Ltd., in 2003. Headquartered in Zhengzhou, China, it functions as a subsidiary of Zhengzhou Auto Industrial Co., Ltd.
Aandeelprijs
$5.15
Laatst gesynchroniseerd: 2026-10-22
Marktkapitalisatie
$2.94B
Verandering (1 dag)
0.97%
Verandering (1 jaar)
-5.80%
Land
CN
Handel Autobio Diagnostics Co., Ltd. (603658)
Categorie
Healthcare
Winst voor Autobio Diagnostics Co., Ltd. (603658)
Winst in Jun 2026 TTM: $169.22M
Volgens de meest recente financiële verslagen van Autobio Diagnostics Co., Ltd. bedraagt de huidige winst van het bedrijf $169.22M. In 2024 behaalde het bedrijf een winst van $176.60M, een daling ten opzichte van de winst van 2023, die $192.49M bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Autobio Diagnostics Co., Ltd. van 2011 tot 2026
Winst aan het einde van elk jaar
| Jaar | Winst | Wijzigen |
|---|---|---|
| 2026 (TTM) | $169.22M | -3.17% |
| 2025 | $174.77M | -1.04% |
| 2024 | $176.60M | -8.25% |
| 2023 | $192.49M | 2.63% |
| 2022 | $187.55M | 11.87% |
| 2021 | $167.65M | 29.68% |
| 2020 | $129.28M | 1.63% |
| 2019 | $127.20M | 33.67% |
| 2018 | $95.16M | 20.21% |
| 2017 | $79.16M | 34.78% |
| 2016 | $58.73M | 17.42% |
| 2015 | $50.02M | 28.06% |
| 2014 | $39.06M | 63.96% |
| 2013 | $23.82M | 27.82% |
| 2012 | $18.64M | 63.64% |
| 2011 | $11.39M | 0.00% |
Winst van vergelijkbare bedrijven of concurrenten
| Bedrijf | Winst | Winstverschil | Land |
|---|---|---|---|
| $7.87B | 4,550.10% |
US
|
|
| $4.82B | 2,747.14% |
US
|
|
| $-252.70M | -249.33% |
US
|
|
| $4.12B | 2,335.02% |
CN
|
|
| $1.66B | 879.78% |
US
|
